Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.
作者信息
Zern Emily K, Cheng Susan, Wolfson Aaron M, Hamilton Michele A, Zile Michael R, Solomon Scott D, Kittleson Michelle M
机构信息
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (E.K.Z., S.C., M.A.H., M.M.K.).
Sarver Heart Center, University of Arizona, Tucson (A.M.W.).
出版信息
Circ Heart Fail. 2020 Feb;13(2):e006696. doi: 10.1161/CIRCHEARTFAILURE.119.006696. Epub 2020 Feb 14.
Abstract
摘要
相似文献
1
Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.血管紧张素受体-中性肽链内切酶抑制剂疗法可逆转终末期心力衰竭等待移植患者的肺动脉高压。
Circ Heart Fail. 2020 Feb;13(2):e006696. doi: 10.1161/CIRCHEARTFAILURE.119.006696. Epub 2020 Feb 14.
2
Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon?沙库巴曲缬沙坦治疗心力衰竭：是时候成为典范了吗？
J Cardiovasc Pharmacol. 2020 Feb;75(2):105-107. doi: 10.1097/FJC.0000000000000782.
3
PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction.先锋-心力衰竭（PIONEER-HF）：在射血分数降低的心力衰竭管理中，中性肽链内切酶抑制作用的新前沿。
Cardiovasc Res. 2019 Nov 1;115(13):e136-e139. doi: 10.1093/cvr/cvz223.
4
In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?沙库巴曲缬沙坦院内起始治疗：急性失代偿性心力衰竭的新范式？
J Cardiovasc Pharmacol. 2019 Jul;74(1):1-3. doi: 10.1097/FJC.0000000000000685.
5
Is the glass half full or half empty after PARAGON-HF?在PARAGON-HF研究之后，这杯水是半满还是半空？
Cardiovasc Res. 2020 Jan 1;116(1):e5-e7. doi: 10.1093/cvr/cvz326.
6
Sacubitril/valsartan (Entresto) for heart failure.沙库巴曲缬沙坦（恩格列净）用于治疗心力衰竭。
Med Lett Drugs Ther. 2015 Aug 3;57(1474):107-9.
7
Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.血管紧张素受体脑啡肽酶抑制剂用于射血分数降低的心力衰竭患者：来自台湾的真实世界经验
J Cardiovasc Pharmacol Ther. 2020 Mar;25(2):152-157. doi: 10.1177/1074248419872958. Epub 2019 Sep 12.
8
Angiotensin Receptor-Neprilysin Inhibition.血管紧张素受体-中性内肽酶抑制作用
J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):356-364. doi: 10.1177/1074248416683049. Epub 2016 Dec 28.
9
Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.沙库巴曲缬沙坦起始治疗后的心脏逆向重构及预后
Circ Heart Fail. 2020 Jun;13(6):e006946. doi: 10.1161/CIRCHEARTFAILURE.119.006946. Epub 2020 Jun 2.
10
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.血管紧张素受体脑啡肽酶抑制剂治疗功能性二尖瓣反流。
Circulation. 2019 Mar 12;139(11):1354-1365. doi: 10.1161/CIRCULATIONAHA.118.037077.
引用本文的文献
1
Who is the Candidate? The Heart Transplant Evaluation Process.谁是候选人？心脏移植评估过程。
Methodist Debakey Cardiovasc J. 2025 May 15;21(3):13-24. doi: 10.14797/mdcvj.1512. eCollection 2025.
2
Sacubitril/Valsartan Improves Hemodynamic Parameters of Pulmonary and Systemic Circulation in Patients Awaiting Heart Transplantation.沙库巴曲缬沙坦改善等待心脏移植患者的肺循环和体循环血流动力学参数。
J Clin Med. 2025 Apr 8;14(8):2539. doi: 10.3390/jcm14082539.
3
Risk Factors for Adverse Outcomes in Connective Tissue Disease-Associated Pulmonary Hypertension.结缔组织病相关肺动脉高压不良结局的危险因素
Rev Cardiovasc Med. 2025 Mar 17;26(3):26877. doi: 10.31083/RCM26877. eCollection 2025 Mar.
4
Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.苏根/低氧诱导的大鼠肺动脉高压的生物学和药理学的最新概述。
J Aerosol Med Pulm Drug Deliv. 2024 Oct;37(5):241-283. doi: 10.1089/jamp.2024.0016.
5
Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial.血管紧张素受体脑啡肽酶抑制剂对恩格列净改善射血分数降低的慢性心力衰竭患者心脏结构和功能疗效的影响：Empire HF试验
Am Heart J Plus. 2023 Feb 3;26:100264. doi: 10.1016/j.ahjo.2023.100264. eCollection 2023 Feb.
6
Management of pulmonary hypertension associated with valvular heart disease with angiotensin-receptor neprilysin inhibitor.血管紧张素受体脑啡肽酶抑制剂治疗瓣膜性心脏病相关肺动脉高压
Pulm Circ. 2023 Nov 5;13(4):e12303. doi: 10.1002/pul2.12303. eCollection 2023 Oct.
7
The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure.沙库巴曲缬沙坦在心力衰竭相关肺动脉高压中的新作用。
Front Cardiovasc Med. 2023 May 18;10:1125014. doi: 10.3389/fcvm.2023.1125014. eCollection 2023.
8
The history and mystery of sacubitril/valsartan: From clinical trial to the real world.沙库巴曲缬沙坦的历史与奥秘：从临床试验到现实世界
Front Cardiovasc Med. 2023 Mar 28;10:1102521. doi: 10.3389/fcvm.2023.1102521. eCollection 2023.
9
Characteristics and Predictors of Late Right Heart Failure After Left Ventricular Assist Device Implantation.左心室辅助装置植入后晚期右心衰竭的特征和预测因素。
ASAIO J. 2023 Mar 1;69(3):315-323. doi: 10.1097/MAT.0000000000001804. Epub 2022 Oct 2.
10
Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension.新兴疗法：钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂、胰高血糖素样肽1（GLP1）激动剂以及血管紧张素受体脑啡肽酶抑制剂（ARNI）治疗肺动脉高压的潜在作用
Pulm Circ. 2022 Jan 18;12(1):e12028. doi: 10.1002/pul2.12028. eCollection 2022 Jan.
本文引用的文献
1
Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.沙库巴曲缬沙坦治疗血管紧张素Ⅱ受体阻滞剂和脑啡肽酶抑制剂相关肺动脉高压
Circ Heart Fail. 2019 Nov;12(11):e005819. doi: 10.1161/CIRCHEARTFAILURE.119.005819. Epub 2019 Nov 11.
2
Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.奈普利酶抑制对各种利钠肽检测的影响。
J Am Coll Cardiol. 2019 Mar 26;73(11):1273-1284. doi: 10.1016/j.jacc.2018.12.063.
3
Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial.奈普利肽抑制肺动脉高压：一项随机、双盲、安慰剂对照、概念验证试验。
Br J Pharmacol. 2019 May;176(9):1251-1267. doi: 10.1111/bph.14621. Epub 2019 Mar 31.
4
The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update.2016年国际心肺移植学会心脏移植列入标准：十年更新
J Heart Lung Transplant. 2016 Jan;35(1):1-23. doi: 10.1016/j.healun.2015.10.023.
5
Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat.双重内皮素转换酶/中性内肽酶抑制剂对大鼠心功能障碍性肺动脉高压发展的保护作用。
Pediatr Pulmonol. 2010 Nov;45(11):1076-85. doi: 10.1002/ppul.21290.
6
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.利钠肽与磷酸二酯酶5抑制剂之间的协同作用可改善肺动脉高压。
Am J Respir Crit Care Med. 2008 Oct 15;178(8):861-9. doi: 10.1164/rccm.200801-121OC. Epub 2008 Aug 8.
Zotero 插件